JP7221694B2 - 心血管状態におけるセマグルチド - Google Patents
心血管状態におけるセマグルチド Download PDFInfo
- Publication number
- JP7221694B2 JP7221694B2 JP2018556411A JP2018556411A JP7221694B2 JP 7221694 B2 JP7221694 B2 JP 7221694B2 JP 2018556411 A JP2018556411 A JP 2018556411A JP 2018556411 A JP2018556411 A JP 2018556411A JP 7221694 B2 JP7221694 B2 JP 7221694B2
- Authority
- JP
- Japan
- Prior art keywords
- semaglutide
- pharmaceutical composition
- subject
- mace
- fatal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 title claims description 124
- 108010060325 semaglutide Proteins 0.000 title claims description 124
- 229950011186 semaglutide Drugs 0.000 title claims description 123
- 230000002526 effect on cardiovascular system Effects 0.000 title claims description 64
- 238000000034 method Methods 0.000 claims description 77
- 208000010125 myocardial infarction Diseases 0.000 claims description 65
- 239000000902 placebo Substances 0.000 claims description 62
- 229940068196 placebo Drugs 0.000 claims description 62
- 230000034994 death Effects 0.000 claims description 52
- 231100000517 death Toxicity 0.000 claims description 52
- 206010019280 Heart failures Diseases 0.000 claims description 47
- 230000000250 revascularization Effects 0.000 claims description 38
- 230000002829 reductive effect Effects 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 26
- 206010002388 Angina unstable Diseases 0.000 claims description 24
- 208000007814 Unstable Angina Diseases 0.000 claims description 24
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 21
- 230000007211 cardiovascular event Effects 0.000 claims description 16
- 230000001934 delay Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000011866 long-term treatment Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 description 47
- 208000024172 Cardiovascular disease Diseases 0.000 description 44
- 230000003111 delayed effect Effects 0.000 description 30
- 238000003384 imaging method Methods 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 14
- 230000000977 initiatory effect Effects 0.000 description 13
- 229940127017 oral antidiabetic Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000747 cardiac effect Effects 0.000 description 9
- 230000003442 weekly effect Effects 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 208000032109 Transient ischaemic attack Diseases 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 201000010875 transient cerebral ischemia Diseases 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 230000002641 glycemic effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 230000024924 glomerular filtration Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
- 206010052337 Diastolic dysfunction Diseases 0.000 description 3
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 3
- 102000005561 Human Isophane Insulin Human genes 0.000 description 3
- 108010084048 Human Isophane Insulin Proteins 0.000 description 3
- 102000016261 Long-Acting Insulin Human genes 0.000 description 3
- 229940100066 Long-acting insulin Drugs 0.000 description 3
- 206010027525 Microalbuminuria Diseases 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 206010062237 Renal impairment Diseases 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 108010071377 human long-acting insulin Proteins 0.000 description 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000012633 nuclear imaging Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010057573 Chronic hepatic failure Diseases 0.000 description 2
- 206010011376 Crepitations Diseases 0.000 description 2
- 208000010334 End Stage Liver Disease Diseases 0.000 description 2
- 206010073153 Familial medullary thyroid cancer Diseases 0.000 description 2
- 206010016803 Fluid overload Diseases 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 229940122199 Insulin secretagogue Drugs 0.000 description 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 2
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000011444 chronic liver failure Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000011863 diuretic therapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000012153 long-term therapy Methods 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 229940090048 pen injector Drugs 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000009662 stress testing Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 206010005144 Bleeding varicose vein Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006580 Bundle branch block left Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 206010013974 Dyspnoea paroxysmal nocturnal Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 206010051448 Hepatojugular reflux Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101500028773 Homo sapiens Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
- 206010052341 Impaired insulin secretion Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010022840 Intraventricular haemorrhage Diseases 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 208000009378 Low Cardiac Output Diseases 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 206010073149 Multiple endocrine neoplasia Type 2 Diseases 0.000 description 1
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010031123 Orthopnoea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 208000004327 Paroxysmal Dyspnea Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000001434 dietary modification Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229940029980 drug used in diabetes Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229940127208 glucose-lowering drug Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 208000012144 orthopnea Diseases 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16167458.5 | 2016-04-28 | ||
| EP16167458 | 2016-04-28 | ||
| EP16188262.6 | 2016-09-12 | ||
| EP16188262 | 2016-09-12 | ||
| PCT/EP2017/060160 WO2017186896A1 (en) | 2016-04-28 | 2017-04-28 | Semaglutide in cardiovascular conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514925A JP2019514925A (ja) | 2019-06-06 |
| JP2019514925A5 JP2019514925A5 (https=) | 2020-06-18 |
| JP7221694B2 true JP7221694B2 (ja) | 2023-02-14 |
Family
ID=58668875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018556411A Active JP7221694B2 (ja) | 2016-04-28 | 2017-04-28 | 心血管状態におけるセマグルチド |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US12569543B2 (https=) |
| EP (1) | EP3448416B1 (https=) |
| JP (1) | JP7221694B2 (https=) |
| KR (3) | KR20180135012A (https=) |
| CN (1) | CN109069589B (https=) |
| AU (2) | AU2017256774B2 (https=) |
| BR (1) | BR112018072020A2 (https=) |
| CA (1) | CA3022535A1 (https=) |
| CL (1) | CL2018003045A1 (https=) |
| DK (1) | DK3448416T3 (https=) |
| ES (1) | ES2928007T3 (https=) |
| HR (1) | HRP20221150T1 (https=) |
| HU (1) | HUE060040T2 (https=) |
| IL (1) | IL262390B1 (https=) |
| MA (1) | MA44762A (https=) |
| MX (1) | MX2018012700A (https=) |
| MY (1) | MY202967A (https=) |
| PH (1) | PH12018502274B1 (https=) |
| PL (1) | PL3448416T3 (https=) |
| RS (1) | RS63630B1 (https=) |
| RU (1) | RU2768283C2 (https=) |
| SI (1) | SI3448416T1 (https=) |
| WO (1) | WO2017186896A1 (https=) |
| ZA (2) | ZA202507394B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7221694B2 (ja) | 2016-04-28 | 2023-02-14 | ノヴォ ノルディスク アー／エス | 心血管状態におけるセマグルチド |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| HRP20230929T1 (hr) * | 2018-10-26 | 2023-11-24 | Novo Nordisk A/S | Stabilni pripravci semaglutida i njihova upotreba |
| CN113194929B (zh) * | 2018-12-21 | 2022-12-09 | 诺和诺德股份有限公司 | Glp-1肽的喷雾干燥工艺 |
| PE20230819A1 (es) * | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| CN114699510B (zh) * | 2021-12-29 | 2024-07-16 | 浙江湃肽生物有限公司 | 一种司美格鲁肽微针阵列及其制备方法 |
| AU2023285400A1 (en) * | 2022-06-08 | 2024-12-05 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
| CN117462654A (zh) * | 2023-09-28 | 2024-01-30 | 武汉大学人民医院（湖北省人民医院） | 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008533105A (ja) | 2005-03-18 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | アシル化ｇｌｐ−１化合物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002316811A1 (en) * | 2001-06-28 | 2003-03-03 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| WO2003084563A1 (en) * | 2002-04-04 | 2003-10-16 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
| TR201906789T4 (tr) | 2003-11-20 | 2019-05-21 | Novo Nordisk As | Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları. |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| JP5662453B2 (ja) | 2009-10-02 | 2015-01-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物の治療上の使用 |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CA3070513C (en) * | 2010-05-05 | 2023-01-03 | Boehringer Ingelheim International Gmbh | A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis |
| KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| MX377589B (es) * | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP2753642B8 (en) | 2011-09-06 | 2017-12-13 | Novo Nordisk A/S | Glp-1 derivatives |
| US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
| JP6374862B2 (ja) | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体 |
| US20150290294A1 (en) | 2012-11-02 | 2015-10-15 | Mansoor Husain | Methods for inhibiting platelet aggregation using glp-1 receptor agonists |
| WO2014124860A1 (en) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Specific pde4b-inhibitors for the treatment of diabetes mellitus |
| EP2968344A1 (en) | 2013-03-15 | 2016-01-20 | Boehringer Ingelheim International GmbH | Use of linagliptin in cardio- and renoprotective antidiabetic therapy |
| MX369818B (es) * | 2013-11-15 | 2019-11-22 | Novo Nordisk As | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| US10894054B2 (en) | 2015-04-07 | 2021-01-19 | Intercept Pharmaceuticals, Inc. | FXR agonist compositions for combination therapy |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| JP7221694B2 (ja) * | 2016-04-28 | 2023-02-14 | ノヴォ ノルディスク アー／エス | 心血管状態におけるセマグルチド |
-
2017
- 2017-04-28 JP JP2018556411A patent/JP7221694B2/ja active Active
- 2017-04-28 MX MX2018012700A patent/MX2018012700A/es unknown
- 2017-04-28 KR KR1020187033310A patent/KR20180135012A/ko not_active Ceased
- 2017-04-28 US US16/097,032 patent/US12569543B2/en active Active
- 2017-04-28 HR HRP20221150TT patent/HRP20221150T1/hr unknown
- 2017-04-28 HU HUE17721109A patent/HUE060040T2/hu unknown
- 2017-04-28 KR KR1020257007151A patent/KR20250038818A/ko active Pending
- 2017-04-28 SI SI201731219T patent/SI3448416T1/sl unknown
- 2017-04-28 DK DK17721109.1T patent/DK3448416T3/da active
- 2017-04-28 CN CN201780026303.2A patent/CN109069589B/zh active Active
- 2017-04-28 EP EP17721109.1A patent/EP3448416B1/en active Active
- 2017-04-28 WO PCT/EP2017/060160 patent/WO2017186896A1/en not_active Ceased
- 2017-04-28 AU AU2017256774A patent/AU2017256774B2/en active Active
- 2017-04-28 CA CA3022535A patent/CA3022535A1/en active Pending
- 2017-04-28 PH PH1/2018/502274A patent/PH12018502274B1/en unknown
- 2017-04-28 RU RU2018140900A patent/RU2768283C2/ru active
- 2017-04-28 KR KR1020227036550A patent/KR102778218B1/ko active Active
- 2017-04-28 RS RS20220901A patent/RS63630B1/sr unknown
- 2017-04-28 MY MYPI2018703725A patent/MY202967A/en unknown
- 2017-04-28 BR BR112018072020-8A patent/BR112018072020A2/pt unknown
- 2017-04-28 ES ES17721109T patent/ES2928007T3/es active Active
- 2017-04-28 PL PL17721109.1T patent/PL3448416T3/pl unknown
- 2017-04-28 MA MA044762A patent/MA44762A/fr unknown
-
2018
- 2018-10-15 IL IL262390A patent/IL262390B1/en unknown
- 2018-10-25 CL CL2018003045A patent/CL2018003045A1/es unknown
-
2024
- 2024-10-04 AU AU2024227113A patent/AU2024227113A1/en active Pending
-
2025
- 2025-01-15 US US19/023,039 patent/US20250288649A1/en active Pending
- 2025-05-02 US US19/197,677 patent/US20250262281A1/en active Pending
- 2025-09-03 ZA ZA2025/07394A patent/ZA202507394B/en unknown
- 2025-09-03 ZA ZA2025/07395A patent/ZA202507395B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008533105A (ja) | 2005-03-18 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | アシル化ｇｌｐ−１化合物 |
Non-Patent Citations (5)
| Title |
|---|
| Exp Diab Res., 2011, Vol.2011, Article.215764(p.1-10) |
| Ｔｈｅ Ｌａｃｃｅｔ Ｄｉａｂｅｔｅｓ ＆ Ｅｎｄｏｃｒｉｎｏｌｏｇｙ，Ｅｌｓｅｖｉｅｒ，2015年08月11日，３，９，667-669 |
| 循環器内科, 2012, Vol.71 No.5, p.470-476 |
| 日本臨床, 2011, Vol.69 No.5, p.836-841 |
| 糖尿病, 2012, Vol.55, No.Supplement 1, p.S-135 (I-P-177） |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7221694B2 (ja) | 心血管状態におけるセマグルチド | |
| AU2024201937A1 (en) | Liraglutide in cardiovascular conditions | |
| JP7193455B2 (ja) | 心血管状態におけるインスリンデグルデク | |
| CN110099719A (zh) | 用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素 | |
| WO2017149105A1 (en) | Liraglutide in renal conditions | |
| HK1261741A1 (en) | Semaglutide in cardiovascular conditions | |
| HK1261741B (en) | Semaglutide in cardiovascular conditions | |
| WO2017149109A1 (en) | Liraglutide in diabetic foot ulcer | |
| BR122025010585A2 (pt) | Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular | |
| HK1259166B (en) | Liraglutide in cardiovascular conditions | |
| HK1259166A1 (en) | Liraglutide in cardiovascular conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200428 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200428 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210301 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210527 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210901 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220307 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220907 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230104 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230202 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7221694 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |